Jiangsu Hengrui Medicine Co., Ltd
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2016-02-25
- Last Posted Date
- 2020-05-13
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 197
- Registration Number
- NCT02691975
- Locations
- 🇨🇳
Beijing Hosptial, Beijing, Beijing, China
🇨🇳Chinese PLA General Hospital, Beijing, Beijing, China
🇨🇳Chongqing Cancer Hospital, Chongqing, Chongqing, China
A Study of SHR6390 in Advanced Solid Tumor Patients
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2022-07-11
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT02684266
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients
- First Posted Date
- 2016-02-02
- Last Posted Date
- 2016-04-12
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT02671513
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Multiple Doses Escalation Study of SHR0302 in Rheumatoid Arthritis (RA) Patients
- First Posted Date
- 2016-01-28
- Last Posted Date
- 2016-04-19
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT02665910
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
Omega-3-Acid Ethyl Esters 90 Soft Capsules for Lowering Very High Triglycerides
- Conditions
- Interventions
- First Posted Date
- 2015-12-09
- Last Posted Date
- 2015-12-09
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT02625870
Safety and Efficacy Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2015-11-25
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 29
- Registration Number
- NCT02614846
- Locations
- 🇨🇳
Union Hospital Tongji Medical College Huazhong University of Science and technology, Wuhan, Hubei, China
A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2019-06-17
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 79
- Registration Number
- NCT02575651
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳No.307 Hospital, Academy of Military Medical Sciences, Beijing, Beijing, China
The Drug-drug Interaction of SHR3824 and SP2086
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2015-11-25
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT02500485
- Locations
- 🇨🇳
Phase I Unit of Tongji Hospital affilated Tongji Medical School of Huangzhong Science and Thechnology, Wuhan, Hubei, China
Pharmacokinetics of Imrecoxib in Subjects With Hepatic Insufficiency
- First Posted Date
- 2015-05-28
- Last Posted Date
- 2015-05-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT02456688
- Locations
- 🇨🇳
The frist affiliated hospital of Fourth Military Medical University, Xi'an, Shanxi, China
A Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-04-24
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 2004
- Registration Number
- NCT02426034
- Locations
- 🇨🇳
Nanjin Military 81 Hosiptal, Nanjing, Jiangsu, China
🇨🇳Fudan University cancer hospital, Shanghai, Shanghai, China